Community pharmacists in England have launched a new digital platform called My Local Surgery, enabling patients to access Pharmacy First consultations online.
This initiative, a part of the NHS Pharmacy First scheme, facilitates free video consultations for six common conditions, connecting patients with community
pharmacists for clinical advice and treatment.
The platform, spearheaded by a team of pharmacy, tech, and clinical services experts, including experienced community pharmacists Darren Lingaloo and Gulraj
Dhillon, tech specialist Nav Ramiah, and Dr. Adam Kirk, a seasoned NHS and digital healthcare professional, seeks to meet the rising demand for clinical services.
Darren Lingaloo, co-founder and chief pharmacist at My Local Surgery, said: "The evolving role of pharmacists is long overdue and has the potential to save
millions of GP appointments every year.
Online pharmacy PillTime has taken a step to boost its prescription growth by implementing new Patient Medication Record (PMR) system Titan in its
state-of-the-art premises.
PillTime moved to new, expanded 26,000sqft premises in Cribbs Causeway on the edge of Bristol earlier this year, where it has also installed state-of-the-art
robotics in a bid to significantly enhance future productivity and capacity.
Teething problems over Easter weekend saw PillTime struggling to seamlessly integrate all the new systems and processes while physically moving premises which
affected service delivery and customer support.
However, CEO Leighton Humphreys was supported by Tariq Muhammad, CEO of Invatech Health, who is a former community pharmacist and has worked with independent
pharmacies around the UK as well as larger online businesses, to integrate Titan into their workflows.
Alongside integration work, Muhammad and his team supported PillTime with necessary design, governance and pharmacy expertise as the company struggled to meet its
usual high standards for dispensing medicines to patients.
Digital transformation is sweeping across the healthcare landscape. Fuelled by ambitious government policy, exciting innovation and huge injections of funding,
it's hard for anyone in the sector not to catch a dose of digitisation fever.
But digitisation is not a universal tonic, and it certainly isn't always a 'good thing'. In fact, there's a real danger to digitising healthcare. Such a fundamental
change to the very nature of care delivery is an inevitably high-risk process: sometimes things or people get forgotten, vital processes stall, or new systems fail
to replicate the strengths of those they replace. Take, for instance, the digitisation of pharmacies.
Over recent years, the public's use of online-only pharmacies have boomed: in March it was reported that the number of items dispensed from distance-selling
pharmacies in England, UK quadrupled between 2016 and 2021.
These online providers offer an attractively convenient way for patients to receive their medicines; replacing a trip to a high street pharmacy with a package
delivered straight to their door. On the surface, this digital solution seems perfect not only for young patients with busy schedules, but also for older patients
or for those with restricted mobility who may struggle with in-person collection.
Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire.
The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters.
LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been
based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport
connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee
wellbeing.
This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people
living with skin conditions, their families and society.
Alex Potter is the new Managing Director of PharmAssist Solutions UK, an online purchasing solution utilised by over 1,100 community pharmacies. Potter,
previously the Director of Digital at Phoenix UK, will succeed the current MD, Amar Randhawa, and has expertise in the digital landscape across the industry,
PharmAssist Solutions said in a statement.
"We are delighted to have Alex on board," said Stuart Lucas, Chair of the PharmAssist Board. "His profound grasp of the pharmacy sector, combined with his
expertise in digital innovation, will spearhead PharmAssist's evolution to meet the dynamic demands of its clientele."
Meanwhile, Lucas expressed his gratitude and appreciation to Amar for his hard work and dedication over the last decade. "Amar, as the founder of PharmAssist,
played a pivotal role in achieving numerous significant milestones and driving its growth," he added. "We wish him every success in his future endeavors."
British pharmacies and slimming clinics are reducing prices for weight-loss drugs Wegovy and Mounjaro in a competitive bid to win patients.
Both Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (Tirzepatide) injection drugs are cleared for weight loss in combination with a reduced-calorie
diet and increased physical activity. Wegovy was launched in the UK market in September, with Mounjaro following in February.
Initially designed for treating type 2 diabetes, the drugs have been found to also induce weight loss by suppressing appetite and decelerating digestion.
As reported by Reuters, Simple Online Pharmacy has further reduced the price of starter doses of Mounjaro to £149 for a one-month supply. In February, the price
was cut to £159 ($198) from £179. Additionally, the pharmacy on Monday discounted the higher Mounjaro strengths that patients take later.
Online retail giant Amazon said on Tuesday (January 24) it is offering a $5 monthly subscription plan for U.S. Prime members that will cover a range of generic
drugs and their doorstep delivery, furthering the ecommerce giant's push into healthcare.
The program, named RxPass, includes more than 50 medications addressing over 80 chronic conditions such as high blood pressure, anxiety, diabetes and male pattern
baldness, Vin Gupta, Amazon Pharmacy's chief medical officer, has said.
However, customers enrolled in Medicare, Medicaid or any other government healthcare program will not be able to enrol in Amazon Pharmacy's RxPass service.
The average Prime member would save about $100 per year with RxPass, John Love, vice president of Amazon Pharmacy, said. Amazon Prime members in most U.S. states
can sign up for the program from January 24.
The flat $5 charge would be without insurance and on top of the Prime membership fee, which costs $139 per year in the United States.
The new data from NHS England has revealed that more than 100,000 patients were treated for minor illness by their high street pharmacist in just one month.
According to new NHS figures, in June, 118,123 people with minor illnesses such as a sore throat or constipation, or those in need of medicine urgently, received
a same-day consultation with their local pharmacist after calling NHS 111 or their GP practice - an increase of more than four-fifths (83%) on the number in the same
month last year (64,512).
The data comes alongside expanded roles for community pharmacies ahead of winter, announced at the NHS England board meeting today.
"From this week, NHS 111 online can directly refer people to their high street pharmacist for a same-day consultation, rather than patients needing to call the
phone line," said NHS England.
Amanda Pritchard, NHS chief executive, said: "Our local pharmacies ensure hundreds of thousands of people every week get the support and medication they need and
today's figures show that in just one month, over 100,000 patients have also had consultations with their local pharmacist for minor illnesses - this means patients
are getting the care they need quickly but also in a convenient way that can fit in with their busy lives.
Superdrug, one of the leading health and beauty retailers, is all set to invest in 25 new stores this year, expanding its bricks-and-mortar retail footprint.
It confirmed with Pharmacy Business that amongst its 25 new stores there "will be a mix of pharmacy and retail stores".
The venture is expected to create over 570 jobs nationwide, creating a seamless customer experience and providing vital support for high streets and local
communities.
The investment, part of the brand's O+O (Online + Offline) platform strategy to deliver its omnichannel ambitions, is driven by continued strong performance
figures. In Q4 2022 Superdrug reported increased volume and value sales and footfall across both sides of the beauty and health business. Whilst in 2021 revenue
rose 5.1% to £1,168million with a profit before tax increase of 141.3%.
The investment strategy has already seen Superdrug open new stores in Washington Gallery and Falkirk Retail Parks in February 2023 and in Braehead, the largest
Superdrug in Scotland, just last month.
To increase efficiency savings, digital men's health provider Numan has joined forces with Invatech Health to deploy the health tech company's cutting-edge software Titan.
Launched in early 2019, Numan provides medication for 175,000 patients via its Cardiff-based fulfilment operation. A team of its clinicians create personalised treatment plans for the most common male health concerns.
In a statement, Invatech said its Titan software could deliver 20 per cent efficiency savings for Numan whilst supporting the company's ambitious growth plans with improved safety and scalability in processing medications. The new partnership also comes alongside 100 new contracts with community pharmacies around the UK.
Andrew Caple, director of Pharmacy Operations at of Numan, said: "Our findings show that three quarters of men will not visit a doctor when they have a health concern, and we therefore recognise that the online market provides a great opportunity to tackle these problems.
A Orthodontic treatment should be carried out by qualified professionals round this time five years ago there was a surge in the reporting of people
performing DIY orthodontics on themselves in their own homes.
Mainstream media reported that video tutorials had emerged online with instructions on using small elastic bands to adjust teeth positions.
What followed were some horrendous pictures of irreparable damage to people's teeth and gums.
The trend escalated to a point where in 2017, the American Dental Association revealed that 13 per cent of patients had tried some kind of DIY teeth straightening
appliance that had backfired.
Now, we are seeing the situation further evolve, with private companies offering DIY orthodontic treatment under the term 'direct-to-consumer' orthodontics.
The Oral Health Foundation is becoming increasingly concerned with the rise of the DIY orthodontic market and the potential harmful consequences it could have for
millions of consumers.
The Royal Pharmaceutical Society (RPS) has secured a contract with the National Institute for Health Research (NIHR) to deliver a suite of e-learning modules to help pharmacy professionals "become more research active".
The new online resources - due to be launched next summer - are aimed at pharmacists and pharmacy technicians who may not have followed an academic career path or have had little or no experience of research delivery. The e-learning package will allow them to gain new skills so they feel more confident to engage with research and research opportunities.
Nine modules are being developed covering how to transform ideas into a research project, find and evaluate evidence and choose the appropriate research methods
whilst learning how to apply for research funding and deal with governance issues and publication.
At the recent 'Locum Matters' online event held on June 25, 2024, members of the Pharmacists' Defence Association (PDA) discussed critical issues facing
locum pharmacists, with a disturbing trend taking center stage: employers pressuring locum pharmacists to accept lower rates under the threat of potential pharmacy
closures.
The event, organised in response to feedback from PDA locum members, addressed a range of significant topics including training for the recent Pharmacy First
Services, respect for professional autonomy, and the need for adequate rest breaks.
However, the issue of rate pressure and pharmacy closures was a focal point.
Several locum pharmacists reported that some employers were leveraging the possibility of pharmacy closures to coerce them into working for lower pay.
This unethical practice has raised alarm within the locum community, highlighting the precarious working conditions many face.
Chair of the health and social care committee Steve Brine and England's chief pharmacist David Webb are among a raft of speakers who will be addressing
delegates at the 13th Annual Sigma Community Pharmacy Conference to be held in Punta Cana, Dominican Republic from Sunday (March 5).
Day I of the conference will also feature a Q&A session with PSNC CEO Janet Morrison and her lead negotiator Mike Dent, which will be presented as a live webinar
via YouTube for those unable to attend in person.
Sigma Pharmaceuticals has invited all interested community pharmacists and stakeholders in the UK to join the 90 minutes session by clicking this link.
Those joining the session will not only be able to listen to the Q&A session - which will run between 6.30PM and 8.00PM in UK on Sunday - but also ask questions to
the PSNC executives via a live YouTube chat.
Sigma says the operating landscape for community pharmacy has altered dramatically since it last held its 'away conference' in the Philippines in February 2020. The
role of the independents - post pandemic - has rapidly evolved and has now been recognised by the health secretary as playing a significant part in the health of
the nation.
British pharmacy chain Superdrug has announced plans to cease the sale of disposable vapes in all its UK and Ireland stores, citing the environmental impact
caused by its disposal and popularity among young people.
The pharmacy retailer will discontinue selling brands like Vuse GO and Flavaah Bars, with plans to completely clear out existing stock by the end of the year, the
company said in statement.
Superdrug, which previously sold 1,300 single-use vapes weekly, expects a potential impact on revenue stemming from this decision. The company has not yet started
selling vapes online.
"This decision was made to safeguard the environment," the company said on Sept.22, highlighting the risk of fires due to improper disposal of vapes, as many of
them contain lithium batteries.
The VAT penalties regime has had substantial changes with effect from 01 January 2023 and it is important for community pharmacy business owners to take note as
this is a crucial cash inflow for most. Below we explore the changes that will impact all VAT registered community pharmacy businesses.
Old regime
Prior to 01 January 2023, VAT registered businesses that failed to file their VAT returns or pay any VAT liabilities would be subject to the default surcharge regime.
There would be no surcharge for NIL or repayment VAT returns which would apply to most community pharmacy businesses.
New regime
For VAT periods starting on or after 01 January 2023, the default surcharge will be replaced by a new VAT penalties and interest regime if you submit your VAT returns
late or pay your VAT liability late.
If you pay your VAT monthly or quarterly, the deadline for filing your VAT return and paying any VAT liabilities is one calendar month and 7 days after the end of
the respective period. For example, if you are filing the VAT return for the month or quarter ended 30 June 2022, the deadline for filing will be 07 August 2022.
The liability must also be paid and cleared by that date.
Pharmacists with 'relevant experience in a pharmacy setting' can enroll for accredited independent prescribing course, as the General Pharmaceutical Council (GPhC) has decided to scrap the requirement of spending at least two years on the register and having previous experience in a specified clinical or therapeutic area before enrolling for the course.
The GPhC Council meeting held on Thursday instead proposed that applicants must have "relevant experience in a pharmacy setting and be able to recognise, understand
and articulate the skills and attributes required by a prescriber." This experience and awareness will act as the basis of their prescribing practice whilst training.
The regulator noted that the majority of stakeholder organisations, including the Chief Pharmaceutical Officers, the Royal Pharmaceutical Society and the statutory education bodies, were in favour of removing the requirement in a consultation on the topic.
They highlighted that a specific two-year period was not in itself a robust indication of whether an individual was ready to become a prescriber.
They also highlighted that the rapidly developing roles in the profession meant more pharmacists were likely to gain the necessary experience more quickly than in the past. A smaller number of organisations and a larger minority of individuals were opposed, citing that a specific two-year period gave pharmacists the time they needed to develop experience and confidence before being ready to enrol on a course.
Within the last few weeks, at least six pharmacists have been subjected to interim order applications - either suspended or had significant restrictions
placed upon their registration pending a full 'Fitness to Practise' hearing into serious allegations being made about their prescribing practices, the Pharmacists'
Defence Association (PDA) has found.
It said that there has been a "dramatic increase in action being taken by the pharmacy regulator (GPhC) against pharmacist prescribers associated with certain types
of online prescribing services".
It has warned pharmacist prescribers who work for online pharmacies about the specific risks associated with remote prescribing using a questionnaire-based model,
typically with no direct prescriber/patient interaction.
Common features that underpin the allegations include the following: Overreliance on a patient questionnaire to inform clinical decision making; No patient/prescriber
interaction; Prescribing high risk medicines without adequate safeguards; Inadequate systems and processes leading to inappropriate prescribing; Very high volumes
of prescriptions being authorised in short periods of time; and Prescribers/patient relationship established via an unregulated online portal.
Well Pharmacy, a subsidiary company of Bestway Group is donating US$400,000 worth of medicines to help the victims of those impacted by the recent flooding in
Pakistan.
The Bestway Group has raised funds to the tune of $2.3 million, which will be deployed urgently on the ground in Pakistan.
The monies raised has been pledged to build homes (or shelters) for 5,000 families, provide usable water for more than 100,000 individuals and provide food and
medical supplies to over 20,000 people.
In addition to appealing for donations, the Group held a fund-raising event (23 September) at London's Intercontinental on Park Lane, which was attended by over
650 guests including the Lord Chancellor, the Deputy State Bank of Pakistan, UK Cabinet Ministers, and Members of Parliament in addition to leading City' figures
and business community.
The Lord Chancellor Rt Hon Brandon Lewis MP said that the British Government has committed funds of £16.5 million for Pakistan and we are dealing with wider climate
change issues as well and we are committing to that effort.
Jhoots Group, a West Midlands based independent community pharmacy chain, has unveiled plans to expand its digital services after securing a funding worth
£8.23m from HSBC bank.
The new money will allow the groups branches to offer a digital platform for customers to request prescriptions online, enabling the implementation of a hub and
spoke dispensing system to automate prescription deliveries.
The innovation aims to reduce the burden of manual processes on pharmacists, allowing staff to use their time efficiently and support the NHS by offering vaccines
and minor ailment medicine services.
San Jhooty, chief operating officer at Jhoots Group, said: "When faced with the unprecedented challenges of the pandemic, primary and community services came
together to support the community and each other.